Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01212809 · ClinicalTrials.gov registry record · Phase 4

Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles

A Phase 4 study of Intrinsic Aging of Skin, sponsored by Steven Fagien.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT01212809 is a Phase 4 study of Intrinsic Aging of Skin that has completed, run by Steven Fagien. The registered enrollment target is 30 participants. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01212809, a Phase 4 study of Intrinsic Aging of Skin, has completed, sponsored by Steven Fagien.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study is being done to evaluate the differences in the performance of two well known injectable dermal fillers commonly used for the cosmetic treatment of age lines above the lips and on the cheeks when compared to each other in the same patient. The products being tested are Juvéderm® Ultra and CosmoDerm® 1.

Conditions Studied

Interventions

  • DEVICE Juvéderm Ultra
  • DEVICE Cosmoderm 1

Study Locations (1)

Florida

  • Steven Fagien, MD, PA - Boca Raton

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2010-09
Est. Completion 2011-06
Phase Phase 4

Sponsor

Steven Fagien

1 total trials

What the Registry Record Tells You About NCT01212809

The ClinicalTrials.gov registry entry for NCT01212809 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Steven Fagien, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Intrinsic Aging of Skin appearing as the primary indexed condition, and to 2 interventions - of which Juvéderm Ultra is the first listed.

NCT01212809 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.

Frequently Asked Questions

What is clinical trial NCT01212809 about?

NCT01212809 is a clinical study titled "Comparative Study of Reconstituted JUVÉDERM® Ultra vs COSMODERM® 1 for Lip and Cheek Lines, Folds or Wrinkles". This study is being done to evaluate the differences in the performance of two well known injectable dermal fillers commonly used for the cosmetic treatment of age lines above the lips and on the cheeks when compared to each other in the same patient. The products being tested are Juvéderm® Ultra an...

What is the current status of trial NCT01212809?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2010-09. Estimated completion is 2011-06.

What conditions does trial NCT01212809 study?

This clinical trial studies the following conditions: Intrinsic Aging of Skin.

What interventions are being tested in trial NCT01212809?

The interventions under investigation include: Juvéderm Ultra (DEVICE), Cosmoderm 1 (DEVICE).

Who is sponsoring clinical trial NCT01212809?

This trial is sponsored by Steven Fagien, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01212809 being conducted?

This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Intrinsic Aging of Skin

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.